Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma

Published:2019-08 Issue:6 Volume:15 Page:383-386
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Mencel Justin¹²^ORCID,Gargett Tessa³,Karanth Narayan¹,Pokorny Adrian¹,Brown Michael P.²³⁴,Charakidis Michail¹

Affiliation:

1. Department of MedicineRoyal Darwin Hospital Darwin Northern Territory Australia

2. Cancer Clinical Trials UnitRoyal Adelaide Hospital Adelaide South Australia Australia

3. Centre for Cancer BiologyUniversity of South Australia and SA Pathology Adelaide South Australia Australia

4. School of MedicineUniversity of Adelaide Adelaide South Australia Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13233

Reference10 articles.

1. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

2. Thymic hyperplasia associated with primary Sjogren’s syndrome cured by thymectomy

3. Thymus alterations and systemic sclerosis

4. Lambert–Eaton Myasthenic syndrome and follicular thymic hyperplasia in systemic lupus erythematosus

5. Rebound thymic hyperplasia after adrenalectomy in a patient with Cushing syndrome caused by adrenocortical adenoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. [18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors;Handbook of Cancer and Immunology;2023

2. Characterization of immune checkpoint inhibitor‐induced cardiotoxicity reveals interleukin‐17A as a driver of cardiac dysfunction after anti‐PD‐1 treatment;British Journal of Pharmacology;2022-12-13

3. FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls;Seminars in Nuclear Medicine;2020-11

4.

Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway

;Cancer Management and Research;2020-05

5. Ipilimumab/nivolumab;Reactions Weekly;2020-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3